What are the recommended NSAID options for managing an acute gout flare?

NSAID Options for Acute Gout Flare

NSAIDs are an effective first-line treatment option for acute gout flares, with all NSAIDs showing equivalent efficacy—there is no evidence that indomethacin is superior to other NSAIDs like naproxen or ibuprofen. 1

Treatment Approach for Acute Gout

First-Line Anti-Inflammatory Options

The American College of Physicians strongly recommends choosing among three equally effective options for acute gout treatment 1:

• NSAIDs (any non-selective NSAID)
• Corticosteroids (e.g., prednisolone 35 mg for 5 days)
• Colchicine (low-dose: 1.2 mg followed by 0.6 mg 1 hour later)

Corticosteroids should be considered as first-line therapy in patients without contraindications because they are generally safer, lower cost, and have fewer adverse effects than NSAIDs while maintaining equivalent efficacy. 1

NSAID Selection and Equivalency

All NSAIDs demonstrate equivalent efficacy for acute gout—moderate-quality evidence shows no difference between different types of NSAIDs, including indomethacin. 1

• Despite indomethacin being traditionally considered first-line, there is no evidence it is more efficacious than naproxen, ibuprofen, or other NSAIDs 1
• Non-selective NSAIDs and COX-2 inhibitors (COXIBs) show equivalent efficacy for pain reduction, inflammation control, and treatment success 2

Critical Safety Considerations for NSAIDs

NSAIDs carry significant contraindications and adverse effects that must be carefully evaluated: 1

• Gastrointestinal risks: dyspepsia, perforations, ulcers, and bleeding
• Contraindicated in: renal disease, heart failure, cirrhosis
• Non-selective NSAIDs increase adverse events compared to COXIBs: approximately 2-fold increase in withdrawals due to adverse events (RR 2.3) and total adverse events (RR 1.9), mainly gastrointestinal 2

Recent 2025 evidence demonstrates NSAIDs used for gout flare prophylaxis during urate-lowering therapy initiation carry higher cardiovascular risk than colchicine, with increased MACE (HR 1.56) and cardiovascular death (HR 2.50). 3 This suggests avoiding NSAIDs for prophylaxis, though acute flare treatment data remains supportive of NSAID use when appropriate.

Comparative Efficacy: NSAIDs vs. Other Options

NSAIDs versus Corticosteroids:

• Moderate-certainty evidence shows no difference in pain relief (MD 0.1), inflammation (MD 0.3), function (MD -0.2), or treatment success (RR 0.9) 2
• Corticosteroids have fewer total adverse events (RR 1.6 for NSAIDs vs. corticosteroids), particularly lower rates of indigestion (RR 0.50), nausea (RR 0.25), and vomiting (RR 0.11) 4
• Withdrawals due to adverse events are similar between groups 2, 4

NSAIDs versus Placebo:

• Low-certainty evidence suggests NSAIDs may improve pain at 24 hours (47% absolute improvement, RR 2.7) 2
• Little to no effect on inflammation after 4 days or function at 24 hours 2

Clinical Algorithm for NSAID Use in Acute Gout

Step 1: Assess contraindications

• If renal disease (CKD stage ≥3), heart failure, cirrhosis, or high cardiovascular risk → Choose corticosteroids or colchicine instead 1, 3
• If history of GI bleeding/ulcers → Choose corticosteroids or colchicine instead 1

Step 2: If NSAIDs appropriate, select any NSAID

• Naproxen, ibuprofen, or indomethacin are equally effective 1
• Consider COX-2 inhibitor if GI risk factors present but not absolute contraindications 2

Step 3: Monitor and adjust

• Assess response within 24-48 hours 2
• If inadequate response, consider switching to corticosteroids or adding therapy 1

Key Pitfalls to Avoid

• Do not assume indomethacin is superior to other NSAIDs—this is not evidence-based 1
• Do not use NSAIDs in patients with renal disease, heart failure, or cirrhosis—corticosteroids are safer 1
• Avoid NSAIDs for flare prophylaxis during ULT initiation in patients with cardiovascular risk—colchicine is safer 3
• Do not overlook corticosteroids as first-line—they have equivalent efficacy with better safety profile 1, 4